sunitinib accord
accord healthcare s.l.u. - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastické činidlá - gastrointestinal stromal tumour (gist)sunitinib accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sunitinib accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sunitinib accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pnet) with disease progression in adults.
sunitinib vipharm 50 mg
vipharm s.a., poľsko - sunitinib - 44 - cytostatica
sunitinib vipharm 25 mg
vipharm s.a., poľsko - sunitinib - 44 - cytostatica
sunitinib vipharm 12,5 mg
vipharm s.a., poľsko - sunitinib - 44 - cytostatica
sunitinib msn 50 mg tvrdé kapsuly
msn labs europe limited, malta - sunitinib - 44 - cytostatica
sunitinib msn 37,5 mg tvrdé kapsuly
msn labs europe limited, malta - sunitinib - 44 - cytostatica
sunitinib msn 25 mg tvrdé kapsuly
msn labs europe limited, malta - sunitinib - 44 - cytostatica
sunitinib msn 12,5 mg tvrdé kapsuly
msn labs europe limited, malta - sunitinib - 44 - cytostatica
sunitinib teva 50 mg tvrdé kapsuly
teva b.v., holandsko - sunitinib - 44 - cytostatica
sunitinib teva 25 mg tvrdé kapsuly
teva b.v., holandsko - sunitinib - 44 - cytostatica